Shanghai Yizhong (688091.SH) subsidiary's application for clinical trials of the innovative drug YXC-001 has been accepted.

Zhtng Cijng APP News, Shanghai Yizhong (688091.SH) announced that its wholly-owned subsidiary, Shanghai Youxi Chuang Pharmaceutical Technology Co., Ltd., recently received an "Acceptance Notice" from the National Medical Products Administration. The company's self-developed innovative drug YXC-001 (trifunctional antibody fusion protein) for the treatment of advanced solid tumors has officially been accepted for clinical trial application (IND).